{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:34:50Z","timestamp":1747172090928,"version":"3.40.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T23:32:42Z","timestamp":1730849562000},"page":"329.e9-329.e21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical relevance of cut-off percentage for high-grade urothelial carcinoma within low-grade urothelial carcinoma: A determining factor?"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1933-9824","authenticated-orcid":false,"given":"Gozde","family":"Kir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gozde Ecem","family":"Cecikoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2024.10.016_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/01913123.2013.786772","article-title":"The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy","volume":"37","author":"Ajili","year":"2013","journal-title":"Ultrastructural Pathology"},{"issue":"3","key":"10.1016\/j.urolonc.2024.10.016_bib0002","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.10.016_bib0003","article-title":"Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary Carcinomas of the Bladder","author":"Chambers","year":"2024","journal-title":"Int J Surg Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.10.016_bib0004","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1663::AID-CNCR21>3.0.CO;2-8","article-title":"Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma","volume":"88","author":"Cheng","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.016_bib0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4274\/MMJ.galenos.2021.48447","article-title":"The Clinical Impact of Tumor Grade Heterogeneity in Non-muscle-invasive Urothelial Carcinoma of the Bladder","volume":"36","author":"Culpan","year":"2021","journal-title":"Medeni Med J"},{"year":"2004","author":"Eble","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs","key":"10.1016\/j.urolonc.2024.10.016_bib0006"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.016_bib0007","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.juro.2013.11.056","article-title":"Mixed high and low grade bladder tumors\u2013are they clinically high or low grade?","volume":"191","author":"Gofrit","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.10.016_bib0008","article-title":"The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer","volume":"40","author":"Ho","year":"2022"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.016_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anndiagpath.2013.11.002","article-title":"Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence","volume":"18","author":"Hu","year":"2014","journal-title":"Annals of diagnostic pathology"},{"key":"10.1016\/j.urolonc.2024.10.016_bib0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00428-023-03625-3","article-title":"Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma","volume":"483","author":"Kir","year":"2023","journal-title":"Virchows Arch"},{"issue":"17","key":"10.1016\/j.urolonc.2024.10.016_bib0011","doi-asserted-by":"crossref","first-page":"e25693","DOI":"10.1097\/MD.0000000000025693","article-title":"Noninvasive papillary urothelial carcinoma with pathological features in between low and high grades: A case report","volume":"100","author":"Ma","year":"2021","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.016_bib0012","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00345-020-03180-5","article-title":"Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up","volume":"39","author":"Mariappan","year":"2021","journal-title":"World J Urol"},{"year":"2016","author":"Moch","series-title":"WHO Classification of tumours of the urinary system and male genital organs","key":"10.1016\/j.urolonc.2024.10.016_bib0013"},{"year":"1973","author":"Mostofi","series-title":"Histological Typing of Urinary Bladder Tumours","key":"10.1016\/j.urolonc.2024.10.016_bib0014"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.016_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.6004\/jnccn.2009.0004","article-title":"Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis","volume":"7","author":"Nese","year":"2009","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.016_bib0016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jcp.2004.022939","article-title":"Ki-67 MIB1 labelling index and the prognosis of primary Ta T1 urothelial cell carcinoma of the bladder","volume":"59","author":"Quintero","year":"2006","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.016_bib0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2015.09.007","article-title":"Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder","volume":"47","author":"Reis","year":"2016","journal-title":"Human Pathol"},{"key":"10.1016\/j.urolonc.2024.10.016_bib0018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00345-014-1383-5","article-title":"Mixed low-and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome","volume":"33","author":"Schubert","year":"2015","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.10.016_bib0019","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.10.016_bib0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"volume":"8","year":"2022","article-title":"WHO Classification of Tumours Editorial Board","key":"10.1016\/j.urolonc.2024.10.016_bib0021"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:00:03Z","timestamp":1746892803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1078143924006963"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical relevance of cut-off percentage for high-grade urothelial carcinoma within low-grade urothelial carcinoma: A determining factor?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}